Eli Lilly and Co
NYSE:LLY
Eli Lilly and Co
Revenue
Eli Lilly and Co
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$49B
|
CAGR 3-Years
19%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$89.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$47.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$62.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$63.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
4%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Revenue
$9.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
Eli Lilly and Co
Revenue Breakdown
Breakdown by Geography
Eli Lilly and Co
|
Total Revenue:
45B
USD
|
|
United States:
30.4B
USD
|
|
Outside United States:
14.7B
USD
|
|
Europe:
6.9B
USD
|
Breakdown by Segments
Eli Lilly and Co
|
Total Revenue:
45B
USD
|
|
Reportable Segment:
45B
USD
|
|
Net Product Revenue:
40.7B
USD
|
|
Cardiometabolic Health:
7.7B
USD
|
Eli Lilly and Co
Glance View
Eli Lilly and Co. has long been a stalwart in the pharmaceutical industry, sculpting its trajectory through innovation and strategic acumen. Founded in 1876 by Colonel Eli Lilly, the company has grown from a small chemical firm into a global powerhouse in developing life-changing medications. Its headquarters in Indianapolis, Indiana, serve as a hub of research and development, where groundbreaking scientific exploration meets business strategy. Eli Lilly thrives on its core pillars of innovation in oncology, immunology, and diabetes care, relying on a deep commitment to scientific discovery and patient care. This emphasis allows it to consistently bring cutting-edge treatments to market, boosting its reputation as a leader in pharmaceuticals and maintaining a strong pipeline of drugs that drive future growth. The company's business model is principally built around creating proprietary medications that command premium pricing due to their uniqueness and effectiveness. This model sustains Eli Lilly's revenue through a dual approach: serving mature markets with established products and fueling growth with new launches. Patents on flagship drugs protect these revenue streams, allowing the company to invest substantially in research and development, which in recent years prioritizes personalized medicine and biotechnology. Collaborations with academic institutions and other corporations have also been pivotal, accelerating drug development and expanding Eli Lilly's reach across therapeutic areas. Overall, its ability to navigate regulatory frameworks and maintain robust sales and marketing strategies ensures its medications reach patients globally, securing its financial health and influence within the healthcare landscape.
See Also
What is Eli Lilly and Co's Revenue?
Revenue
49B
USD
Based on the financial report for Mar 31, 2025, Eli Lilly and Co's Revenue amounts to 49B USD.
What is Eli Lilly and Co's Revenue growth rate?
Revenue CAGR 10Y
10%
Over the last year, the Revenue growth was 36%. The average annual Revenue growth rates for Eli Lilly and Co have been 19% over the past three years , 16% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet